Additionally, long-term durable outcomes with Olumiant (baricitinib) in pediatric patients 12 years of age and older with severe alopecia areata will be presented from the BRAVE-AA-PEDS clinical trial ...
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the formation of a Scientific Advisory Board (SAB) comprising seven accomplished scientific and industry leaders with deep expertise ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果